It’s no secret that the U.S. is now experiencing an Opioid crisis, with coverage of the issue even making international headlines. The fact that pharmaceutical companies don’t appear to be too bothered by the harm that its legal drugs are causing is also well-known. Now, New York City Mayor Bill de Blasio is giving these companies cause to be concerned with a major lawsuit.
According to the lawsuit, Mayor de Blasio is holding Big Pharma directly responsible for fueling the Opioid crisis, the New York Times reports. This is not the first time that the mayor of NYC is taking legal action against an entire industry, either, since he is also suing Big Oil for its huge role in making climate change the global threat that it is today.
In any case, the legal document pins many of the underlying problems that allowed the Opioid crisis to grow as much as it had on the companies making these drugs. Among the accusations that the lawsuit makes is the misrepresentation of these products as well as encouraging distributors to absolutely flood target cities with opioids.
The companies named in the lawsuit include Purdue Pharma, Teva, Cephalon, Johnson & Johnson, Janssen, Endo, Allergan, and Watson, which is a mix of both manufacturers and distributors. This isn’t the first time that a city actually sued entire industries over the harm that they caused with their products, either.
As Futurism reports, other cities and states have already taken legal action against Big Pharma. There are also examples in recent history that could play a role in how these procedures will go. In the 90s, for example, the tobacco industry was forced to make changes to how it markets its products following the 1998 Tobacco Master Settlement Agreement. If the NYC and other cities’ lawsuits pan out, the same changes could be seen in the pharmaceutical industry.


Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Neuralink Expands Brain Implant Trials with 12 Global Patients
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
New York Declares Measles Disaster Emergency as Cases Surge
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey
NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 



